Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Solid Tumor, Adult × BGB-283 × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor, Adult 1

Interventions

pembrolizumab 4 Proton Therapy 3 toripalimab 1 spartalizumab 1 patritumab deruxtecan 1 osimertinib 1 mirdametinib 1 leronlimab 1 amivantamab 1 Valganciclovir 1 Radiotherapy 1 Paclitaxel 1 Lacteol 1 Interleukin-2 1 Docetaxel 1 Carboplatin 1 Blood Specimen Collection 1 Bevacizumab 1 BGB-283 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03905148 2026-01-07

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

BeOne Medicines

Phase 1 Completed

Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon ⚡